Development of amino acid-modified biodegradable lipid nanoparticles for siRNA delivery
Source abstract
Abstract
The use of siRNA therapeutics to treat cancer is a very promising approach. However, specific delivery of siRNAs to tumors remains a major challenge. The recent success of siRNA delivery to the liver has incentivized the development of biomaterials for siRNA delivery into tumors. Here, we report a new class of amino acid-modified lipids for siRNA delivery to cancer cells. Eight lipids were developed by headgroup modification with histidine and lysine. The lipids were screened in PC3-luciferase stable cells for gene silencing and cellular cytotoxicity study. The best lipid LHHK shows a pKa of 6.08, which is within the optimal pKa range of lipid nanoparticles (LNPs) for siRNA delivery. The LHHK LNP protects siRNA from serum degradation for up to 24 h and shows higher endosomal release and better cellular uptake compared to other lysine-modified lipids in PC3 cells. The LHHK LNP exhibits significant silencing activity of IKKα and IKBKE in prostate cancer and pancreatic cancer, respectively. Moreover, the LHHK LNP encapsulating IKBKE siRNA inhibits cell proliferation of pancreatic cancer cells and suppresses the tumor progression in a pancreatic cancer mouse model. STATEMENT OF SIGNIFICANCE: Lipid nanoparticle (LNP) is a promising platform for siRNA delivery. However, LNP is generally associated with high systemic toxicity. As a result, efficient and biodegradable lipids are highly needed for siRNA-based cancer therapy. Herein, we develop amino acid-modified biodegradable lipids. These lipids show very low cellular toxicity and high transfection efficiency. The best lipid LHHK shows a pKa of 6.08, which is within the optimal pKa range of LNPs for siRNA delivery. The LHHK LNP efficiently silences IKKα and IKBKE in prostate and pancreatic cancer, respectively. Moreover, the LHHK LNP encapsulating IKBKE siRNA inhibits cell proliferation and suppresses tumor growth of pancreatic cancer in vivo. These results suggest that amino acid-modified lipids possess a great potential for siRNA delivery in cancer therapy.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (35)
Show source-provided references
1. The current state and future directions of RNAi-based therapeutics10.1038/s41573-019-0017-4 ↗
2. Delivery materials for siRNA therapeutics10.1038/nmat3765 ↗
3. Lipid nanoparticles enabling gene therapies: from concepts to clinical utility10.1089/nat.2018.0721 ↗
4. Next-generation lipids in RNA interference therapeutics10.1021/acsnano.7b04734 ↗
5. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling10.1038/nbt.2614 ↗
6. Rational design of cationic lipids for siRNA delivery10.1038/nbt.1602 ↗
7. Brief update on endocytosis of nanomedicines10.1016/j.addr.2019.08.004 ↗
8. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs10.1021/acs.nanolett.5b02497 ↗
9. A combinatorial library of lipid nanoparticles for RNA delivery to leukocytes
10. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics10.1038/mt.2013.124 ↗
11. Environment-responsive lipid/siRNA nanoparticles for cancer therapy10.1002/adhm.202001294 ↗
12. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics10.1016/j.jconrel.2015.02.003 ↗
13. Blocking IKKalpha expression inhibits prostate cancer invasiveness10.1007/s11095-010-0351-z ↗
14. Silencing of the IKKepsilon gene by siRNA inhibits invasiveness and growth of breast cancer cells10.1186/bcr2644 ↗
15. Development of cholesteryl peptide micelles for siRNA delivery10.1016/j.jconrel.2013.07.033 ↗
16. Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer10.7150/thno.53102 ↗
17. Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer10.1126/sciadv.abb0616 ↗
18. Advances in siRNA delivery in cancer therapy, artificial cells
19. Lipid nanoparticles for mRNA delivery10.1038/s41578-021-00358-0 ↗
20. Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl310.1073/pnas.2020401118 ↗
21. Imidazole-based synthetic lipidoids for in vivo mRNA delivery into primary T lymphocytes10.1002/anie.202008082 ↗
22. Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection10.1126/sciadv.abb4429 ↗
23. mRNA delivery using bioreducible lipidoid nanoparticles facilitates neural differentiation of human mesenchymal stem cells10.1002/adhm.202000938 ↗
24. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics10.1038/nbt1402 ↗
25. Fast and efficient CRISPR/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger RNA nanoparticles10.1002/adma.201902575 ↗
26. Application of amino acids in the structural modification of natural products: a review10.3389/fchem.2021.650569 ↗
27. Proposals for upper limits of safe intake for methionine, histidine, and lysine in healthy humans10.1093/jn/nxaa231 ↗
28. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity10.1038/ncomms5277 ↗
29. A biomimetic lipid library for gene delivery through thiol-yne click chemistry10.1016/j.biomaterials.2012.07.044 ↗
30. Principles of nanoparticle design for overcoming biological barriers to drug delivery10.1038/nbt.3330 ↗
31. The importance of apparent pKa in the development of nanoparticles encapsulating siRNA and mRNA10.1016/j.tips.2021.03.002 ↗
32. Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery10.1073/pnas.1306529110 ↗
33. Ex vivo red blood cell hemolysis assay for the evaluation of pH-responsive endosomolytic agents for cytosolic delivery of biomacromolecular drugs
34. Branched-tail lipid nanoparticles potently deliver mRNA in vivo due to enhanced ionization at endosomal pH10.1002/smll.201805097 ↗
35. IKBKE is required during KRAS-induced pancreatic tumorigenesis10.1158/0008-5472.CAN-15-1684 ↗